BIOGEN INC.
NASDAQ: BIIB
▲
210.63
+6.69
+3.28%
1 Day
-
Open
205.37
-
Previous Close
203.94
-
Volume (Avg)
800.76k (1.16M)
-
Day's Range
203.92-210.75
-
52Wk Range
187.16-372.12
-
Market Cap.
30.85B
-
Dividend Rate ( Yield)
-
-
Beta
0.39
-
Shares Outstanding
146.45M
-
P/E Ratio (EPS)
20.90 (9.76)
Top Stories
-
FDA and drug makers deepen their commitment to clinical-trial diversity. Will it work?
MarketWatch 4 hrs ago -
Study: Medicare could waste up to $605M on Alzheimer's drug vials
UPI News -
These NC companies will reimburse employees, allow relocation for abortion care
The (Raleigh) News & Observer -
Op-Ed: Overhyped Alzheimer's treatments betrayed patients' hopes. Here's how science should change
LA Times -
Peering Into Biogen's Recent Short Interest
Benzinga 3 days ago -
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
Zacks.com -
Biogen Idec exploring potential sale
ABCNews -
Biogen Idec CEO on Move Back to Cambridge: “We’re Working on It”
Xconomy -
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today
Xconomy -
Biogen Idec
PMLiVE -
Plasmacytoid Dendritic Cells and Immunotherapy in Multiple Sclerosis
Medscape -
Spinal Muscular Atrophy Treatment Market Research 2020 | Industry Growing with Major Key Player Pfizer Inc., Biogen Idec, Boehringer Ingelheim GmbH
Digital Journal -
Global Cancer Treatment Drugs Market with Top Prominent Players like Ipsen, Biogen Idec, Bayer, Teva, Gilead Sciences, Takeda
Digital Journal -
Pregnancy and Fetal Outcomes After Glatiramer Acetate Exposure in Patients With Multiple Sclerosis
Medscape -
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
The New England Journal of Medicine 5/19/2022We report the case of a 54-year-old woman with multiple sclerosis who was treated with delayed-release dimethyl fumarate (DMF; Tecfidera, Biogen Idec) and who died on October 13, 2014, from ...
-
Pre Filled Syringes Global Market Report 2022
Benzinga.com -
Stock News & Analysis
The Motley Fool -
What Price Tysabri?
TheStreet.com
